Syed Osman Ali Ahmed, MBBS, BSc (Hons), MRCP, FRCPath, CCT

Articles by Syed Osman Ali Ahmed, MBBS, BSc (Hons), MRCP, FRCPath, CCT

Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.

How Can Lower-Income Countries Maintain Representation in Clinical Trials?

BySyed Osman Ali Ahmed, MBBS, BSc (Hons), MRCP, FRCPath, CCT

October 27th 2025

Lower- and middle-income countries must work to build trust with pharmaceutical companies to enhance representation in cancer-related clinical trials.

For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.

Region-Based Genetic Disorders Affect Cancer Treatment Decisions

BySyed Osman Ali Ahmed, MBBS, BSc (Hons), MRCP, FRCPath, CCT

October 22nd 2025

In areas that have a higher incidence of genetic conditions, experts across different fields have to collaborate to develop cures and therapies.

Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.

More Global Expertise and Talent Are Needed to Administer Cell Therapies

BySyed Osman Ali Ahmed, MBBS, BSc (Hons), MRCP, FRCPath, CCT

October 21st 2025

Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.

Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].

How Can Cellular Therapies Become More Affordable Across the World?

BySyed Osman Ali Ahmed, MBBS, BSc (Hons), MRCP, FRCPath, CCT

October 20th 2025

Those with cancer may be able to get cellular therapies more affordably if countries and health systems adopt decentralized closed-system manufacturing.